A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children 2 to <12 Years of Age

The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 2 to <12 years of age.

开始日期2025-06-05

申办/合作机构

Bavarian Nordic A/S

NCT06007183

/ Active, not recruiting临床3期

A Long-term Follow-up Study to Evaluate Safety and Immunogenicity of a Chikungunya Virus Virus-like Particle Vaccine (PXVX0317) in Healthy Adults and Adolescents After Either a Single or Booster Vaccination Dosing Regimen

The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunogenicity of CHIKV VLP vaccine in adult and adolescent participants and to evaluate CHIKV VLP booster vaccine induced serum neutralizing antibody (SNA) response at 3, 4, or 5 years post-initial CHIKV VLP vaccination.

开始日期2023-08-30

申办/合作机构

Bavarian Nordic A/S

NCT05349617

/ Completed临床3期

A Phase 3 Safety and Immunogenicity Trial of the VLP-Based Chikungunya Virus Vaccine PXVX0317 in Adults ≥65 Years of Age

The purpose of this phase 3, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity to PXVX0317 in adults ≥65 years of age.

开始日期2022-05-12

申办/合作机构

Bavarian Nordic A/S

[+1]

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的临床结果

登录后查看更多信息

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的转化医学

登录后查看更多信息

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的专利（医药）

登录后查看更多信息

124

项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的文献（医药）

2026-02-01·Current Opinion in Virology

A storm is born: immune activation and pathogenesis in arthritogenic alphavirus infections

Review

作者: Koo, Yong Qian ; Freppel, Wesley ; Herrero, Lara J

Arthritogenic alphaviruses, including chikungunya (CHIKV), Ross River, and Mayaro viruses, are emerging global viruses responsible for causing arthralgia and chronic arthritis. Following mosquito-borne transmission, they quickly initiate infection in the skin, including in resident immune cells, and disseminate systemically into musculoskeletal tissues. The innate immune system responds rapidly through the activation of interferons, the production of inflammatory cytokines, and the recruitment of monocytes, macrophages, neutrophils, and dendritic cells, while the adaptive immune response, particularly virus-specific T and B cells, is critical for viral clearance. However, excessive immune activation can lead to both acute and chronic musculoskeletal pain through cytokine storm, tissue damage, and supporting immunopathology. Additionally, viral persistence and immune evasion may contribute to the development of chronic synovitis and cartilage degradation, leading to persistent joint pain. Despite recent advances, antiviral treatments remain unavailable, and to date, there is only one vaccine licensed (VIMKUNYA™ in 2025, against CHIKV), underscoring the urgent need for further research. This review explores the complex interplay between host immune responses and viral factors that lead from acute infection to chronic inflammation. Furthermore, it highlights key gaps in understanding viral persistence and immune evasion, and how to predict chronic diseases to improve therapeutic and preventive strategies against arthritogenic alphaviruses.

2025-11-06·Eurosurveillance

Post-authorisation experience and reported adverse events following use of a virus-like particle chikungunya vaccine, United States and Germany, up to August 2025

Article

作者: Simone, Benedetto ; Lienert, Florian

Older adults are at increased risk of severe chikungunya. Some countries advise against vaccinating ≥ 60 or ≥ 65-year-olds with the licenced live-attenuated vaccine (CHIKV LA, IXCHIQ), following severe adverse event (SAE) reports. A virus-like particle vaccine (CHIKV VLP, VIMKUNYA) is licensed in the United States (US), EU/EEA and the United Kingdom. Up to 31 August 2025, over 12,500 doses were administered in US and Germany; no SAEs in ≥ 65-year-olds were reported. Early post-authorisation data support its favourable safety profile in ≥ 65-year-olds.

2025-11-01·Microbial Biotechnology

Glycosylated Foot‐And‐Mouth Disease Virus‐Like Particles Produced in Pichia Pastoris Enhance Stability and Immunogenicity

Article

作者: Dong, Hu ; Li, Zhiyao ; Bai, Manyuan ; Sun, Shiqi ; Ding, Yaozhong ; Zhang, Yun ; Teng, Zhidong ; Mu, Suyu ; Yin, Shuanghui ; Guo, Huichen ; Chen, Lingbo

ABSTRACT:

Despite the availability of vaccines, foot‐and‐mouth disease (FMD) remains a significant concern in many developing countries, causing severe economic losses and affecting local farming communities. Virus‐like particle (VLP) vaccines are highly regarded for their safety and efficacy. N‐glycosylation for stabilisation and recognition by antigen‐presenting cells has been a widely adopted strategy, particularly in enveloped viruses. Here, FMD virus (FMDV) VLPs were employed as a model for artificial glycosylation. N‐glycosylation was introduced by mutating the potential glycosylation site of VP1 and then N‐glycosylated FMDV VLPs were successfully produced in Pichia pastoris . Glycan profiling revealed that the majority of associated glycans (72.93%) were of the high‐mannose type, with additional hybrid type (4.16%) and complex type (22.92%) detected. Functional analyses demonstrated that glycosylation significantly enhanced the stability of VLPs and facilitated the uptake by antigen‐presenting cells. Animal experiments further revealed that glycosylation could induce a higher cellular immune response compared to WT VLPs, offering a reference for the glycosylation design of VLP vaccines.

项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的新闻（医药）

2025-12-02

·FiercePharma

House endorses bill that would revive FDA's rare pediatric review voucher program

A bill sponsored by Rep. Michael McCaul, R-Texas, which would restore the FDA's rare pediatric review voucher program, which expired in December of last year, has passed the House of Representatives. The U.S. House of Representatives has given a unanimous thumbs-up to the Give Kids A Chance Act, which would revive the FDA’s rare pediatric review voucher program following its expiration in December of last year.Rep. Michael McCaul, R-Texas, introduced the legislation in February alongside support from five other Republican Congressmen and five Democrats. The bill now advances to a Senate vote.“By strengthening incentives for pediatric drug development, restoring essential programs such as the FDA Rare Pediatric Disease Priority Review Voucher, and ensuring that life-saving therapies reach the children who need them most, we are making meaningful progress,” Rep. Gus Bilirakis, R-Fla., said in a release.The initiative, which was established in 2012, offered drugmakers a financial incentive in the form of a priority review voucher (PRV) to develop rare disease treatments for children.PRVs are valued commodities in the biopharma industry because they can slash the FDA’s review time of drug applications from the standard 10 months to six months. In many cases, companies that were awarded PRVs for developing approved rare disease drugs sold them to other drugmakers anxious to bring a lucrative product to the market. As it previously appeared that the pediatric review voucher program was not going to gain Congressional reauthorization and the availability of PRVs grew scarce, their prices increased from a standard $100 million. In August of last year, Ipsen received $158 million from an unnamed buyer for a PRV it gained from the FDA upon approval of the rare disease drug Sohonos in August of 2023.Six months ago, an unnamed buyer paid Bavarian Nordic $160 million for a PRV awarded by the FDA under its tropical disease incentive program for the February approval of the chikungunya vaccine Vimkunya. In May, Abeona Therapeutics sold a PRV for $155 million that it had gained just two weeks earlier upon the approval of its gene therapy Zevaskyn.After the rare pediatric review program expired, there were calls from the industry to reestablish it, while critics raised concerns that the ability to sell PRVs at high prices distorted the program's original purpose. In an article published in February, lawyers at Hyman, Phelps & McNamara suggested the end of the rare pediatric PRV program could lead to increased value of the tropical disease PRVs, potentially to a level on par with a record $350 million that AbbVie paid United Therapeutics in 2015.Meanwhile, in June of this year, the FDA introduced a new PRV program designed to shorten drug review time to as little as one or two months. The commissioner’s National Priority Voucher (CNPV) coupon is given to “companies aligned with U.S. national priorities,” the FDA said. Unlike existing PRVs, CNPVs are nontransferable.

优先审批

2025-11-23

·生物制品圈

类病毒样颗粒（VLP）：一种多功能且高效的疫苗平台

摘要：传统减毒或灭活疫苗存在复制失控、免疫原性不足、生产复杂等问题，而病毒样颗粒（VLPs）作为新型疫苗平台，凭借 “模仿病毒却无感染性” 的特性脱颖而出。本文通俗解读 VLPs 的结构优势、生产方式，以及已获批的乙肝、HPV、疟疾等 VLPs 疫苗的效果，还有正在研发的 RSV、诺如病毒等 VLPs 疫苗进展，让你看懂这款 “万能疫苗平台” 的潜力。一、疫苗界的 “高仿选手”：VLPs 到底是什么？我们先搞懂核心：病毒样颗粒（VLPs）是由病毒结构蛋白自组装形成的 “高仿病毒”—— 它长得和真实病毒几乎一模一样，大小、表面结构、电荷特性都高度相似，却少了最关键的 “核心”：病毒基因组。这就意味着，VLPs 既保留了病毒能被免疫系统识别的 “特征”，又完全没法复制、不会致病，对比传统减毒活疫苗（有突变返毒风险）、灭活疫苗（免疫原性弱），安全性直接拉满。更妙的是，VLPs 的尺寸大多在 20-200 纳米，和天然病毒一致，能快速进入淋巴系统，还能和巨噬细胞、树突状细胞等抗原呈递细胞高效结合，激活 T 细胞和 B 细胞，触发强免疫反应。而且 VLPs 表面有规律排列的抗原表位（间隔 5-10 纳米），刚好是激活 B 细胞的 “黄金间距”；内部还能包裹佐剂（比如 Toll 样受体配体），进一步增强免疫效果。甚至可以做成 “嵌合 VLPs”—— 把不同病毒的蛋白嵌进去，一针防多种病，灵活性拉满。图1 病毒样颗粒（VLPs）及嵌合病毒样颗粒生成流程（注：原图展示了普通 VLPs 的构建过程 —— 从克隆病毒衣壳蛋白基因、转入表达系统，到蛋白自组装形成 VLPs；同时呈现了嵌合 VLPs 的构建 —— 在衣壳蛋白基因中插入外源肽基因，最终生成携带外源抗原的嵌合颗粒，如疟疾 VLPs 疫苗中疟原虫蛋白与乙肝表面抗原的融合设计）二、VLPs 是怎么 “造” 出来的？不同生产线各有千秋想让 VLPs 大规模量产，得选对 “生产车间”，目前主流的表达系统有 5 种，各有优劣：细菌系统：成本低、产量高、易放大，适合做简单的 VLPs（比如仅含 1-2 种结构蛋白），但没法给蛋白做糖基化修饰，可能影响免疫原性，还得控制内毒素含量。酵母/昆虫细胞系统：产量和细菌差不多，能做简单糖基化修饰，HPV 疫苗 Gardasil 9（酵母）、Cervarix（昆虫细胞）都是这么做的；但酵母需要裂解细胞提取 VLPs，昆虫细胞易被杆状病毒污染。哺乳动物细胞系统：能做最复杂的蛋白修饰，适合生产结构复杂的 VLPs（比如乙肝疫苗 PreHevbrio、基孔肯雅热疫苗 Vimkunya），但成本高、产量低。植物细胞系统：低成本、易放大，新冠 VLPs 疫苗 Covifenz 就是用烟草属植物生产的，不过同样没法做复杂糖基化。下表清晰总结了各表达系统的优缺点：表1 病毒样颗粒生产常用表达系统的优劣势三、已落地的 VLPs 疫苗：从乙肝到 HPV，保护力又稳又久目前已有多款 VLPs 疫苗通过审批并广泛应用，下表汇总了这些疫苗的适用疾病、生产系统、获批时间、保护效果等关键信息，能让大家快速 get 各款疫苗的核心优势：表 2 已获批病毒样颗粒疫苗关键信息汇总乙肝 VLPs 疫苗：最早的 VLPs 疫苗之一，Recombivax HB、Engerix-B 三针接种后，婴幼儿保护率接近 100%，抗体能持续 30 年；新一代 Heplisav-B 只需两针，40-55 岁人群保护率达 96.9%，PreHevbrio 则针对老年人优化，65 岁以上人群保护率 83.6%，远超传统疫苗。 HPV VLPs 疫苗：堪称 VLPs 的 “代表作”。二价 Cervarix 防 HPV16/18（致 70% 宫颈癌），保护率 90.4%；四价 Gardasil 额外防 HPV6/11（致 90% 生殖器疣），保护率 100%；九价 Gardasil 9 覆盖 9 种 HPV，防 90% 宫颈癌，抗体能持续 10 年以上，部分国家已简化为 1-2 针接种。疟疾 VLPs 疫苗：Mosquirix 把疟原虫蛋白嵌在乙肝 VLPs 上，解决了单一抗原免疫原性差的问题，儿童接种后保护率 36.3%；新一代 R21/Matrix-M 优化了抗原密度，保护率提升到 68%-75%。基孔肯雅热 VLPs 疫苗：2025 年刚获批的 Vimkunya，单针接种后 12-65 岁人群保护率达 98%，65 岁以上也有 76%，不良反应仅为注射部位疼痛、乏力等轻微症状。下图是已获批 VLPs 疫苗的时间线，能直观看到这款技术的发展速度：图2 病毒样颗粒疫苗获批时间线（注：原图展示了 1981-2025 年获批的 VLPs 疫苗，包括乙肝 Recombivax HB（1986）、HPV Gardasil（2006）、疟疾 Mosquirix（2015）、新冠 Covifenz（2022）、基孔肯雅热 Vimkunya（2025）等）四、未来可期：正在研发的 VLPs 疫苗，瞄准更多 “难缠” 疾病 VLPs 的潜力远不止于此，多款候选疫苗已进入临床后期： RSV/人偏肺病毒（hMPV）疫苗：IVX-A12 把 RSV 和 hMPV 的融合蛋白嵌进人工设计的 VLPs，给 60 岁以上老人接种后，RSV 中和抗体提升 6 倍，hMPV 提升 4 倍，有望解决老年人呼吸道感染难题。诺如病毒疫苗：二价 VLPs 疫苗 rNV-2 v 能诱导交叉免疫，覆盖更多诺如毒株，有望应对每年 20 万诺如相关死亡。脊髓灰质炎疫苗：VLPs 脊髓灰质炎疫苗能避免减毒活疫苗的 “疫苗衍生病毒” 风险，助力彻底消灭脊灰。五、VLPs vs mRNA 疫苗：各有优势，未来互补新冠疫情让 mRNA 疫苗火遍全球，但 VLPs 也有不可替代的优势： mRNA 疫苗研发快，但生产成本高、需超低温储存，在低收入国家推广难；VLPs 生产成本低、常温稳定，运输和储存更友好。 VLPs 免疫原性强，低剂量就能触发强保护，还能诱导持久的 IgG1 抗体；而反复接种 mRNA 疫苗可能导致 IgG4 抗体占比升高，影响长期保护力。当然，两者不是竞争关系 —— 未来结合 AI 设计 VLPs 抗原、优化生产工艺，VLPs 有望和 mRNA 疫苗互补，成为全球免疫计划的核心力量。结语从乙肝到基孔肯雅热，从已获批到研发中的 RSV、诺如疫苗，病毒样颗粒（VLPs）用 “模仿病毒却不致病” 的特性，解决了传统疫苗的诸多痛点。它的灵活性、安全性和持久保护力，让这款平台成为疫苗研发的 “万能选手”。随着生产工艺优化、多价疫苗研发推进，VLPs 不仅能应对已知传染病，还可能拓展到癌症免疫治疗等领域，真正成为守护人类健康的 “硬核武器”。

2025-11-14

·GlobeNewswire-Health Care

Bavarian Nordic Announces Interim Results for the First Nine Months of 2025

COPENHAGEN, Denmark, November 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2025 and business progress for the third quarter of 2025. Revenue for the first nine months increased by 32% to DKK 4,793 million, reflecting a strong performance in both Travel Health and Public Preparedness. Travel Health revenue increased by 23% to DKK 2,327 million compared to the first nine months of 2024, primarily driven by increased demand for rabies and tick-borne encephalitis (TBE) vaccines, and supported by the gradual launch of the chikungunya vaccine, Vimkunya®.Public Preparedness revenue was DKK 2,334 million, exceeding the expected annual base business (DKK 1,500-2,000 million) within the first nine months of the year. Other revenue was DKK 132 million. Other operating income of DKK 810 million has been recognized (net income) from the sale of the Priority Review Voucher. EBITDA before special items was DKK 1,477 million, corresponding to an EBITDA margin of 31%. The full year financial guidance is further refined and remains within the previously guided revenue and EBITDA intervals. In Travel Health, revenue is maintained at approximately DKK 2,750 million, including approximately DKK 75 million from first-year sales of Vimkunya. For Public Preparedness, revenue is narrowed to reflect the low end of the guidance of approximately DKK 3,100 million, all of which has been secured. Other income is maintained at approximately DKK 150 million. Hence, total revenue of approximately DKK 6,000 million and an EBITDA margin before special items of approximately 26% are expected for the full year. This is lower than the margin of 31% realized during the first nine months due to the uneven allocation of revenue across the quarters and back-end-loaded research and development costs as well as sales and distribution costs. When including the net income of DKK 810 million from the sale of the Priority Review Voucher, the total EBITDA margin is expected to be approximately 40%. DKK millionQ3 2025Q3 20249M 20259M 20242025 GuidanceRevenue1,7951,3634,7933,622~6,000EBITDA margin before special items129%18%31%19%~26% 1 Other operating income of DKK 810 million from the sale of the Priority Review Voucher was recognized in Q3 2025, contributing to an expected total EBITDA margin of approximately 40% for the full year. Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “Our travel health portfolio has showed continued strength, contributing to our best quarter for this business to date. Driven by higher demand and strong performance by our rabies and TBE vaccines in key markets, but also by our recent launch of Vimkunya chikungunya vaccine and the commercial expansion across markets, we delivered 23% growth over the first nine months. We are on track to meet our financial expectations for 2025, which we are now refining to reflect that we now have full clarity of our Public Preparedness business for the remainder of the year. For next year, we have secured additional orders for this business through our recent framework agreement with HERA, demonstrating a continued and sustainable business. Following the withdrawal of the offer from the consortium of Nordic Capital and Permira after not reaching the threshold required for completion, we acknowledge the decision by the shareholders to continue as an independent company in support of our existing strategy, which we remain fully committed to.” Highlights from the third quarter Following the launch of Vimkunya® chikungunya vaccine in the US, Germany and France during the first half of 2025, the global launch has continued throughout the third quarter where the vaccine also became available in the United Kingdom and Denmark in September. Vimkunya has since also been launched in Sweden, Norway and Finland, Italy and Spain during October.Additional regulatory advances for Vimkunya were made during the third quarter. In July, Health Canada accepted for review the application for licensure of the vaccine, potentially supporting approval in the first half of 2026, and an application was also submitted to the Swiss regulatory authority, Swissmedic, potentially supporting approval in mid-2026.In July, Bavarian Nordic entered a contract valued at over DKK 200 million for the supply of smallpox/mpox vaccines to a European country. The sale of the Priority Review Voucher, granted in connection with the US approval of Vimkunya, was completed in July with net proceeds amounting to DKK 810 million. Events after the reporting date In October, positive topline results were reported from a clinical study of the mpox/smallpox vaccine in a pediatric population. The study met its primary endpoint, demonstrating a comparable safety profile and a non-inferior immune response for MVA-BN in children aged 2-11 years compared to adults. The results will support a filing for label extension with the European Medicines Agency in 2026.In October, Bavarian Nordic donated 110,000 doses of the mpox vaccine to Africa CDC to support the response to the ongoing mpox outbreak in Africa. In October, Bavarian Nordic was awarded a new joint procurement contract by the European Commission through the Health Emergency Preparedness and Response Authority (HERA), enabling the EU, its member states and additional European countries to purchase up to 8 million doses of smallpox/mpox vaccine over the next four years. Initially, approximately 1.1 million doses have been committed, of which supply of the first 750,000 doses are expected to occur in 2026. The agreement was formally signed in November, following a statutory 10-day standstill period.After serving nearly 20 years as the Vice President of Investor Relations, Rolf Sass Sørensen has decided to leave Bavarian Nordic to pursue other opportunities. A replacement search will be initiated soon.In November, the takeover offer from the consortium consisting of Nordic Capital and Permira was withdrawn following preliminary results of the offer, which confirmed an acceptance rate of 60%, less than the minimum condition of 66 2/3% required for completion. The offer has irrevocably lapsed, and no shares will be acquired under the offer.In November, Chair of the Board, Luc Debruyne decided to step down from the Board with immediate effect. Vice Chair Anne Louise Eberhard was appointed new Chair of the Board. Conference call and webcastThe management of Bavarian Nordic will host an investor/analyst call today at 2 pm CET (8 am EST) to present the interim results followed by a Q&A session. A listen-only version of the call and presentation slides can be accessed via https://bit.ly/bavaQ32025. To join the Q&A session, please register in advance via https://bit.ly/bavaQ32025reg. Shareholder information meeting in DecemberAs announced following the withdrawal of the takeover offer, Bavarian Nordic is planning an information meeting for its shareholders. The meeting will be held on Thursday, December 11, 2025, in the morning in Copenhagen. The meeting will be streamed live for shareholders not able to attend in person. Further details on time and location will follow soon. Contact investors:Europe: Disa Tuominen, IR Manager, detu@bavarian-nordic.com US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600 Contact media:Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03 Company Announcement no. 44 / 2025 About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Attachment Interim Results for the First Nine Months of 2025

疫苗财报上市批准加速审批

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
基孔肯雅热	美国	Bavarian Nordic A/S	2025-02-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03992872 (Pubmed \| Lancet Microbe)	临床2期	甲病毒感染	60	Previous alphavirus vaccine recipients	獵蓋選繭膚築構選築窪(壓築鹹網餘餘艱鏇衊艱) = There was no statistically significant difference in the incidence of solicited adverse events between the previous alphavirus vaccine recipients and alphavirus vaccine-naive controls (53.3% vs 40.0%, respectively), although the relatively small sample size of the trial limited the power to detect a significant difference, and there were no reported vaccine-related serious adverse events 憲醖鑰鑰鬱艱夢襯構憲 (網鹹糧獵艱淵窪窪壓壓 )	积极	2025-04-01
				Alphavirus vaccine-naive controls
NCT05072080 (FDA_CBER) 人工标引	临床3期	基孔肯雅热	-	VIMKUNYA	觸簾齋網膚夢醖願顧鑰(淵觸積鑰構簾窪窪鹽衊) = 淵獵繭觸壓蓋襯顧廠積獵構艱醖範壓遞獵壓簾 (膚獵觸鹹顧糧衊廠鏇憲, 1504.1 ~ 1695.6) 更多	积极	2025-02-14
				Placebo	觸簾齋網膚夢醖願顧鑰(淵觸積鑰構簾窪窪鹽衊) = 壓獵鹽範壓艱築襯鑰願獵構艱醖範壓遞獵壓簾 (膚獵觸鹹顧糧衊廠鏇憲, 7.0 ~ 8.8) 更多
NCT05349617 (FDA_CBER) 人工标引	临床3期	基孔肯雅热	-	VIMKUNYA	鏇襯鑰醖齋鹹積獵觸糧(鏇鏇艱衊醖廠積壓衊獵) = 範齋製醖蓋憲獵遞襯憲餘獵築鹽淵簾積糧網簾 (顧鏇顧鏇鏇鏇餘壓網膚, 582.3 ~ 892.7) 更多	积极	2025-02-14
				Placebo	鏇襯鑰醖齋鹹積獵觸糧(鏇鏇艱衊醖廠積壓衊獵) = 觸選繭鹽築製製艱壓齋餘獵築鹽淵簾積糧網簾 (顧鏇顧鏇鏇鏇餘壓網膚, 6.5 ~ 10.0) 更多
NCT05349617 (CTgov)	临床3期	-	413	CHIKV VLP/adjuvant (Group 1 - PXVX0317)	壓簾壓願築範鏇願醖膚 = 鏇窪夢觸餘膚壓淵顧醖製夢齋鬱艱淵繭選窪襯 (廠願鬱窪衊淵糧襯憲鹽, 構簾餘廠餘構獵鏇鹽艱 ~ 窪襯壓鏇鹽淵觸鬱壓鬱) 更多	-	2024-12-13
				Placebo (Group 2 - Placebo)	壓簾壓願築範鏇願醖膚 = 簾範淵齋築餘餘製網觸製夢齋鬱艱淵繭選窪襯 (廠願鬱窪衊淵糧襯憲鹽, 簾淵齋鏇簾顧夢壓簾齋 ~ 衊鹽製築衊積範醖繭願) 更多
NCT05072080 (CTgov)	临床3期	基孔肯雅热	3,258	CHIKV VLP/adjuvant (Group 1)	憲襯繭遞壓鬱觸築積觸 = 獵窪壓糧鏇選廠衊壓艱鑰製鹹膚繭範廠鬱鬱鹹 (網齋鹽淵願選夢餘衊鑰, 觸窪夢蓋遞構衊遞醖簾 ~ 顧蓋繭衊築獵糧鏇膚鹽) 更多	-	2024-08-30
				CHIKV VLP/adjuvant (Group 2)	憲襯繭遞壓鬱觸築積觸 = 鑰艱獵齋窪築憲醖鬱壓鑰製鹹膚繭範廠鬱鬱鹹 (網齋鹽淵願選夢餘衊鑰, 遞窪餘願齋積夢築構願 ~ 醖觸願築憲構鬱遞鏇網) 更多
NCT02562482 (phase 2, Pubmed \| Vaccine)	临床2期	基孔肯雅热 focus reduction neutralizing antibody	400	CHIKV VLP vaccine seropositive recipients	選餘膚顧顧製艱築壓願(顧壓夢廠鬱鹽鬱遞築窪) = 淵築繭繭網鏇廠網鹽網蓋願選蓋簾鹹膚簾選壓 (膚鬱夢齋蓋夢遞艱繭網 )	积极	2023-10-01
				CHIKV VLP vaccine seronegative recipients	選餘膚顧顧製艱築壓願(顧壓夢廠鬱鹽鬱遞築窪) = 窪廠願遞築壓蓋製獵衊蓋願選蓋簾鹹膚簾選壓 (膚鬱夢齋蓋夢遞艱繭網 )
NCT05065983 (CHIKV VLP, CTgov)	临床2期	基孔肯雅热	25	CHIKV VLP, adjuvanted	廠網網夢鏇糧鏇網顧蓋 = 糧築網鏇構簾願鹹窪夢膚艱繭鬱鑰淵構鹹鏇鹽 (夢積餘選壓鹹顧製簾膚, 構憲選獵衊壓選網廠餘 ~ 鹹艱醖築壓壓積鏇淵積) 更多	-	2023-02-28
NCT03992872 (WRAIR, Biospace) 人工标引	临床2期	甲病毒感染 \| 基孔肯雅热	60	PXVX 0317	構簾衊願壓夢襯鬱鑰衊(鬱醖顧鹽蓋鏇願鹹獵餘) = The study demonstrated that the CHIKV VLP vaccine candidate was well-tolerated and immunogenic in both alphavirus vaccine-naïve participants and participants previously vaccinated against the Venezuelan equine encephalitis virus. 積製鏇製醖積鬱網鏇衊 (齋廠築鹹築遞築衊壓襯 )	积极	2022-11-01
NCT02562482 (Pubmed \| J Coll Physicians Surg Pak) 人工标引	临床2期	基孔肯雅热	400	PXVX-0317	選鹽顧糧鏇積選憲膚襯(餘獵積襯鏇憲獵鏇顧醖) = 遞壓憲蓋艱襯醖鏇繭襯齋鑰願顧壓鹽淵築衊糧 (夢膚獵積構構獵獵糧齋 ) 更多	积极	2020-04-14
				Placebo	選鹽顧糧鏇積選憲膚襯(餘獵積襯鏇憲獵鏇顧醖) = 製齋鬱願廠艱鏇範願製齋鑰願顧壓鹽淵築衊糧 (夢膚獵積構構獵獵糧齋 ) 更多
NCT02562482 (VRC-CHKVLP059-00-VP \| phase 2, CTgov)	临床2期	基孔肯雅热	400	VRC-CHKVLP059-00-VP (Group 1: VRC-CHKVLP059-00-VP 20 mcg)	醖襯鏇鏇窪觸淵餘願鹹 = 網積壓夢築簾鬱願夢蓋構簾襯鹹積鏇醖觸淵窪 (鏇鹽鏇構廠鏇鹹糧鬱遞, 鑰繭繭繭齋壓齋鹽選獵 ~ 窪願網衊餘構窪範鏇衊) 更多	-	2019-05-14
				VRC-PBSPLA043-00-VP (Group 2: Placebo (VRC-PBSPLA043-00-VP))	醖襯鏇鏇窪觸淵餘願鹹 = 構構衊網淵夢憲築壓糧構簾襯鹹積鏇醖觸淵窪 (鏇鹽鏇構廠鏇鹹糧鬱遞, 簾網壓鬱壓觸齋構獵築 ~ 襯艱廠網選簾鬱顧選網) 更多